These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12942854)

  • 1. [Preclinical evaluation of the safety of biotechnology products: specific aspects].
    Descotes J; Ravel G; Vial T
    Therapie; 2003; 58(2):139-43. PubMed ID: 12942854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.
    Snodin DJ; Ryle PR
    BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues with biotechnology products in toxicologic pathology.
    Terrell TG; Green JD
    Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation of biotechnology products.
    Zbinden G
    Drug Saf; 1990; 5 Suppl 1():58-64. PubMed ID: 2182064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.
    Brennan FR; Shaw L; Wing MG; Robinson C
    Mol Biotechnol; 2004 May; 27(1):59-74. PubMed ID: 15122047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relevance of pharmacokinetics in the development of biotechnology products.
    Toon S
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):93-103. PubMed ID: 8839682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of biotechnology products for therapeutic use.
    Sims J
    Toxicol Lett; 2001 Mar; 120(1-3):59-66. PubMed ID: 11323162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. An attempt to transfer current experience into future testing strategies.
    Teelmann K; Hohbach C; Lehmann H
    Arch Toxicol; 1986 Dec; 59(4):195-200. PubMed ID: 3548648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical safety of biotechnology products intended for human use. Proceedings of a satellite symposium of the IV International Congress of Toxicology. Tokyo, Japan, July 26, 1986.
    Prog Clin Biol Res; 1987; 235():1-213. PubMed ID: 3601998
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety Pharmacology Evaluation of Biopharmaceuticals.
    Amouzadeh HR; Engwall MJ; Vargas HM
    Handb Exp Pharmacol; 2015; 229():385-404. PubMed ID: 26091648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung.
    Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE
    Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxicology: role in the safety assessment of drugs.
    Descotes J
    Drug Saf; 2005; 28(2):127-36. PubMed ID: 15691223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of biological and biotechnology-derived medicines.
    Dayan AD
    Toxicology; 1995 Dec; 105(1):59-68. PubMed ID: 8638284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.